Evidence-Based Medicine

Primary Ovarian Insufficiency (POI)

Primary Ovarian Insufficiency (POI)

Background

  • Primary ovarian sufficiency (POI) refers to hypergonadotropic hypogonadism in women before age 40 years.
  • POI results from depletion or dysfunction of ovarian follicles due to genetic, iatrogenic, autoimmune, or idiopathic causes.
  • POI presents with delayed or absent menarche or oligo/amenorrhea in addition to other symptoms of menopause, such as hot flashes and vaginal dryness.
  • Untreated it results in a number of complications including osteoporosis, hypercholesterolemia, cardiovascular disease, impaired sexual function, and impaired well-being.

Evaluation

  • Suspect diagnosis of primary ovarian insufficiency in adolescents with normal sexual characteristics who have not reached menarche by age 15 years, and women aged < 40 years with amenorrhea for ≥ 4 months or < 9 menses per year and symptoms of estrogen deficiency.
  • Exclude pregnancy as a cause of amenorrhea (Strong recommendation).
  • Measure follicle stimulating hormone (FSH) and estradiol twice, at least 1 month apart. Diagnosis is confirmed with the presence of FSH levels > 40 units/L and estradiol level < 50 pg/mL (Strong recommendation).
  • Other tests to consider when primary ovarian insufficiency is suspected include thyroid-stimulating hormone (TSH), prolactin, luteinizing hormone (LH), karyotype evaluation to detect X chromosome abnormalities, and genetic screening to detect premutation of the FMR1 gene.
  • For women who wish to become pregnant, consider ovarian reserve tests (ORT) to determine oocyte reserve and quality (Weak recommendation).

Management

  • Offer either hormone replacement therapy or combination oral contraceptives until the typical age of natural menopause (Strong recommendation).
  • Testosterone therapy can be considered to improve libido and sexual function in women with surgically-induced menopause, however androgen treatment is supported by limited data and women should be advised that long-term health effects are unclear (Weak recommendation).
  • Use nonhormonal contraceptive methods (for example, barrier methods) for women who do not desire to become pregnant (Strong recommendation). Oral contraceptives will not prevent ovulation and pregnancy.

Published: 08-07-2023 Updeted: 08-07-2023

References

  1. De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet. 2010 Sep 11;376(9744):911-21
  2. Cordts EB, Christofolini DM, Dos Santos AA, Bianco B, Barbosa CP. Genetic aspects of premature ovarian failure: a literature review. Arch Gynecol Obstet. 2011 Mar;283(3):635-43
  3. Torrealday S, Kodaman P, Pal L. Premature Ovarian Insufficiency - an update on recent advances in understanding and management. F1000Res. 2017;6:2069
  4. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI., Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, Cifkova R, de Muinck Keizer-Schrama S, Hogervorst E, Janse F, Liao L, Vlaisavljevic V, Zillikens C, Vermeulen N. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016 May;31(5):926-37

Related Topics